valve

valve_in_valve-compressor

Lower Mismatch Rate with the New Self-Expandable Valves

Prosthesis mismatch (PPM) was introduced by Rahimtoola in 1978 and happens when the effective orifice area of a heart valve&nbsp;prosthesis&nbsp;is too small in relation to patient&nbsp;body size. Surgical valves have been well documented, but there is little information on percutaneous valves. The study looked at 757 patients undergoing TAVR with pre and post procedural eco-Doppler<a href="https://solaci.org/en/2019/11/25/lower-mismatch-rate-with-the-new-self-expandable-valves/" title="Read more" >...</a>

AHA 2019 | GALILEO-4D: rivaroxabán y prevención de engrosamiento y trombosis de las valvas post TAVI

AHA 2019 | GALILEO-4D: Rivaroxaban in the Prevention of Post TAVR Valve Thickening and Thrombosis

This sub study of the GALILEO specifically looked at valve thickening and reduced leaflet motion after TAVR documented with 4D CT. Whether anticoagulation with rivaroxaban might reduce or prevent this phenomenon remained unanswered.  Patients receiving the same anticoagulation scheme than the general study’s (rivaroxaban + aspirin vs. aspirin + clopidogrel) were assessed by 4D CT<a href="https://solaci.org/en/2019/11/20/aha-2019-galileo-4d-rivaroxaban-in-the-prevention-of-post-tavr-valve-thickening-and-thrombosis/" title="Read more" >...</a>

valve_in_valve-compressor

Europe Grants Approval to Balloon-Expandable Valve in Low-Risk Patients; Self-Expanding Valve Still Waiting for It

The balloon-expandable valve has been granted approval in Europe for treatment of the complete risk spectrum of symptomatic severe aortic stenosis. Europe has recently approved an expanded indication for the Sapien 3 system for use in low-risk patients, as reported by Edward Lifesciences. Sapien 3, which includes the next-generation Sapien 3 Ultra, is the first transcatheter heart valve<a href="https://solaci.org/en/2019/11/15/europe-grants-approval-to-balloon-expandable-valve-in-low-risk-patients-self-expanding-valve-still-waiting-for-it/" title="Read more" >...</a>

Mismatch protésico en válvulas supra anulares y en válvulas intra anulares

Prosthesis Mismatch in Supra and Intra Annular valves

The self-expandable valve was associated to lower prosthesis-patient mismatch (PPM) compared against the balloon expandable valve regardless annular area, according to this study soon to be published in J Am Coll Cardiol Intv. This difference was basically driven by patients with larger body surface area (&gt;1.83m²). Prosthesis mismatch has been associated to increased mortality after transcatheter<a href="https://solaci.org/en/2019/10/30/prosthesis-mismatch-in-supra-and-intra-annular-valves/" title="Read more" >...</a>

Trombólisis local en tromboembolismo pulmonar

Incidence and Prognosis of Heart Valve Embolization

The incidence of peri-procedural transcatheter heart valve embolization and migration (TVEM) is as low as 1%. However, it is associated with increased morbidity and mortality. Peri-procedural TVEM is one of the most feared complication given its potential to transform the procedure into a catastrophe, but little do we know about its incidence (except for a<a href="https://solaci.org/en/2019/10/24/incidence-and-prognosis-of-heart-valve-embolization/" title="Read more" >...</a>

Reparación de la válvula tricúspide con la técnica del Mitra Clip

More Evidence on Tricuspid Valve Repair

While still lacking large-scale randomized trials, evidence is slowly building for transcatheter tricuspid valve repair. This work, presented at the TCT 2019 Congress and simultaneously published in JACC, shows that transcatheter tricuspid valve repair is not only feasible, but also likely to reduce the rates of mortality and heart failure rehospitalization compared with medical therapy alone.<a href="https://solaci.org/en/2019/10/18/more-evidence-on-tricuspid-valve-repair/" title="Read more" >...</a>

Miami Valves 2020| 50% off para miembros SOLACI

Miami Valves 2020 | 50% off for SOLACI Members

Focused on transcatheter therapies for the treatment of structural cardiomyopathy and valvulopathy, Miami Valves 2020 is coming up. This annual meeting is taking place from January 16 to 18 at the luxurious Marriott Miami Biscayne Bay, in beautiful Miami, in Florida, USA. As a result of the close collaboration between SOLACI and Miami Valves, SOLACI<a href="https://solaci.org/en/2019/10/16/miami-valves-2020-50-off-for-solaci-members/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs. Medical Treatment in Patients With Severe Tricuspid Regurgitation

Courtesy of the SBHCI. Discover the results of the this study, presented during TCT Congress 2019.   Link to the SBHCI publication HERE Original Title: A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs. Medical Treatment in Patients With Severe Tricuspid Regurgitation. Author of the original title: Maurizio Taramasso. We are interested in your opinion. Please,<a href="https://solaci.org/en/2019/09/30/tct-2019-a-propensity-score-matched-analysis-of-transcatheter-tricuspid-valve-treatment-vs-medical-treatment-in-patients-with-severe-tricuspid-regurgitation/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses

Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had<a href="https://solaci.org/en/2019/09/30/tct-2019-mitral-valve-in-valve-1-year-results-for-sapien-3-in-mitral-valve-replacement-for-degenerated-bioprostheses/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Courtesy of the SBHCI. Discover the results of the PARTNER 3 study, presented during TCT Congress 2019.   Link to the SBHCI publication HERE Original Title: PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves. Author of the original title: Raj Makkar. We are interested in your opinion. Please,<a href="https://solaci.org/en/2019/09/30/tct-2019-partner-3-low-risk-computed-tomography-substudy-subclinical-leaflet-thrombosis-in-transcatheter-and-surgical-bioprosthetic-valves/" title="Read more" >...</a>

Top